ICU Medical (NASDAQ:ICUI) Given New $200.00 Price Target at Piper Sandler

ICU Medical (NASDAQ:ICUI) had its price target lifted by Piper Sandler from $195.00 to $200.00 in a report released on Friday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the medical instruments supplier’s stock.

A number of other research firms also recently weighed in on ICUI. Weiss Ratings upgraded shares of ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. KeyCorp upped their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Zacks Research downgraded shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $195.20.

ICU Medical Stock Performance

ICUI stock traded up $4.46 during mid-day trading on Friday, hitting $172.11. 464,850 shares of the company were exchanged, compared to its average volume of 219,459. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.30 billion, a PE ratio of 72.01, a price-to-earnings-growth ratio of 2.04 and a beta of 0.88. The business has a 50 day simple moving average of $162.91 and a 200-day simple moving average of $149.27. ICU Medical has a 1-year low of $113.37 and a 1-year high of $192.85.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.30. The company had revenue of $556.22 million during the quarter, compared to analysts’ expectations of $552.03 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. ICU Medical’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.03 earnings per share. On average, equities analysts forecast that ICU Medical will post 7.22 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In related news, COO Christian B. Voigtlander sold 8,929 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the sale, the chief operating officer owned 37,377 shares of the company’s stock, valued at approximately $6,837,374.61. This represents a 19.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the transaction, the insider owned 3,076 shares of the company’s stock, valued at approximately $548,512.32. This represents a 42.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 21,830 shares of company stock worth $3,905,003. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Several institutional investors and hedge funds have recently bought and sold shares of ICUI. Allworth Financial LP bought a new position in shares of ICU Medical in the second quarter worth $26,000. Versant Capital Management Inc grew its position in ICU Medical by 26.2% during the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 65 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in ICU Medical during the second quarter worth about $51,000. Rockefeller Capital Management L.P. increased its stake in ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 146 shares during the last quarter. Finally, Nykredit A S bought a new position in ICU Medical in the 2nd quarter worth about $135,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. Q3 results and guidance
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. BTIG rating update
• Neutral Sentiment: Management will present at the Jefferies Global Healthcare Conference in London on November 15–18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Conference announcement

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.